INTRODUCTION {#sec1-1}
============

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disorder of the central nervous system.\[[@ref1]\] The principal therapeutic option available for this disease consists of immunomodulators like interferon-beta (IFN-β), which reduce the frequency of exacerbations and control the activity and progression of MS.\[[@ref2]\] The use of this drug is followed by certain usual side effects, like secondary dermatological manifestations, which are normally seen as skin reactions where there has been subcutaneous application.\[[@ref2][@ref3]\]

Cutaneous reactions at injection sites are frequently observed (in 44% of patients), ranging from benign painful erythema to skin necrosis.\[[@ref4]\] With the increasing use of recombinant alpha and IFN-β therapy for the treatment of various disorders in recent years, cases of interferon-associated necrotic ulcers have been reported in the literature. Further studies are required to determine the potential role that inflammatory chemokines may play in the development of this rare side effect of IFN-β treatment. We report a case of extensive interferon-associated necrotic ulcers occurring at the injection site of a patient using subcutaneous IFN-β-1b for the treatment of MS.

CASE REPORT {#sec1-2}
===========

A 49-year-old female with relapsing-remitting MS received immune modulating therapy with recombinant IFN-β-1b, 8 million IU, by subcutaneous injection given alternately in thighs and arms every other day. In addition, baclofen, Amantadine were orally taken daily. After 3 months of interferon injections, erythematous patches and plaques developed at the injection sites and gradually progressed to areas of indurated erythema with central necrotic ulceration. Initially the lesions were transient, but after several weeks the erythematous skin at the site of the lesions became fixed. The lesions were painful. The patient did not exhibit fever, weight loss, arthralgias, or myalgias. She had no history of drug allergies. She denied any previous history of connective tissue disorders or other underlying coagulation or bleeding disorders. Skin examination revealed necrotic ulcers of 6--8 cm in diameter on both thighs and smaller necrotic ulcers on both arms \[[Figure 1](#F1){ref-type="fig"}\]. There was no lymph node enlargement. Initially, she was diagnosed with cellulitis and treated with antibiotics, but when the lesions failed to resolve, she was referred to us. The differential blood count and the blood chemistry were within normal limits. Blood cultures were negative. Gram and periodic acid-Schiff staining were also negative. X-rays of both thighs and arms revealed no osteomyelitis. An ultrasound of the necrotic ulcer showed soft tissue edema without any fluid collections. Histological evaluation was conducted before treatment on the patient who had consented to a skin biopsy. Two deep skin biopsies were obtained from wedge from floor and margin altogether. They showed nonspecific inflammatory reactions including acantosis, hyperkeratosis, psudoepithelial hyperplasia, hyperplastic changes of blood vessels, and occasionally vessel thrombi with perivascular lymphocytic and neutrophilic infiltration \[[Figure 2](#F2){ref-type="fig"}\]. No evidence of vasculitis and granulomatous reactions was seen. Direct immunofluorescence with staining for C3, IgG, IgA, and IgM was negative. We diagnosed the lesions as skin and soft tissue necrosis secondary to IFN-β-1b injection. Treatment consisted of stopping the subcutaneous IFN-β-1b injections and switching to a different IFN-β preparation that is injected intramuscularly once a week. She was also referred to a plastic surgeon for surgical debridement. Her arm ulcers were excised, and the sites were sutured closed \[[Figure 3](#F3){ref-type="fig"}\]. The thigh lesions were left to heal by secondary intention after some suture repair to reduce the size of the wound areas. Strict wound care and skin grafting was also performed \[Figures [3](#F3){ref-type="fig"}--[5](#F5){ref-type="fig"}\]. With this regimen, the patient\'s skin lesions improved over the course of the following year.

![Severe necrotizing cutaneous lesions in the patient treated with interferon beta-1b. Necrotic skin ulcers with surrounding erythema were seen on the right arm (a) and on the left thigh (b)](JRPP-4-99-g001){#F1}

![Histopathological finding of necrotic lesions associated with interferon beta-1b injection. Nonspecific inflammatory reactions without evidence of obvious vasculitis.](JRPP-4-99-g002){#F2}

![Primary closure of necrotic ulcer of right arm (a) and left arm (b) at the injection site after surgical debridement](JRPP-4-99-g003){#F3}

![Surgical debridement followed by secondary intention of the interferon-associated necrotic ulcers, seen on the right thigh (a) and on the left thigh (b)](JRPP-4-99-g004){#F4}

![Wound healing at the injection site of interferon beta-1b: After 5 months, on arms (a and c), by suturing and on thighs by secondary intention scarring (b)](JRPP-4-99-g005){#F5}

DISCUSSION {#sec1-3}
==========

Interferons are natural glycoproteins that have antiviral, antiproliferative, and immune regulatory functions. There are several classes of interferons including interferon alpha, beta, and gamma. Interferons alpha and beta are used worldwide in the treatment of several diseases including MS.\[[@ref5]\] Three IFN-β formulations are currently approved for the treatment of relapsing-remitting MS: Subcutaneous IFN-β-1b, intramuscular IFN-β-1a, and subcutaneous IFN-β-1a.\[[@ref1]\] In general, all IFN-β formulations are well-tolerated. Furthermore, improvements in injection technique, adverse effect management, and patient education have contributed to greater patient compliance with treatment regimens.\[[@ref6]\] However, the administration of IFN-β is associated with the risk of a variety of adverse effects.\[[@ref7]\] The most common of these are flu-like symptoms and in patients who receive subcutaneous injections, injection-site reactions.\[[@ref7]\] The side effects that have been reported can be divided into class-specific and agent-specific effects. Class-specific side effects of IFN-β include fever, myalgias, arthralgias, and influenza-like symptoms beginning 2--6 h after injection and abating within 24 h.\[[@ref6]\] In addition, IFN-β-1b is associated with agent-specific side effects, particularly injection-site reactions.\[[@ref6]\] These injection-site reactions are usually mild and self-limited, but in rare cases they may become more severe, and may sometimes necessitate the discontinuation of therapy. Injection-site reactions are not uncommon and are mostly seen in female patients. They normally manifest as localized erythema without induration that is not severe.\[[@ref8]\] Severe skin reactions with necrotic ulceration are rare. The pathogenic mechanisms of the severe skin reactions are not fully understood. The pathologic mechanisms of immunologically-mediated necrotizing vasculitis and platelet-dependent thrombosis in the dermis, which are similar to the mechanism of action of IFN-β in terms of receptor sites and immunological outcomes, could be involved.\[[@ref4]\] Some reports have suggested that the vasospastic effects of IFN-β-1b, along with small arteriolar thromboses located in the deep subcutaneous fat, may be responsible for necrosis.\[[@ref9]\] More recently, Buttmann *et al*. demonstrated direct induction of local chemokine expression and associated immune cell extravasation caused by IFN-β in human skin biopsy specimens.\[[@ref10]\] In a literature review, we identified nine cases in which complications of IFN-β treatment were related to the injection area, as they are in our study. These are summarized in [Table 1](#T1){ref-type="table"}.\[[@ref9][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17]\] The mean age of the subjects in these nine cases is 44 years (34--62 years); seven are women, and two are men. The interval between beginning treatment with interferon and the appearance of symptoms ranges from 1 to 6 months, with a mean of 3 months. The areas most used for injections, the abdomen, and thighs, are the most common locations for the lesions. Our patient\'s lesions were on her thighs and arms, where she received her injections. In five of the reported cases, biopsy specimens were taken. In all five cases, lymphocytes were the main cell type in the lesions, which was also the case with our patient. The five biopsy specimens also showed perivascular dermatitis. In three of the biopsy specimens, there was thrombosis of dermal vessels.

###### 

Clinical and pathological characteristics of interferon associated cutaneous necrotic ulcer presented in previous reports

![](JRPP-4-99-g006)

It remains unclear exactly how IFN-β-1b therapy should best be handled. Switching from a subcutaneous to an intramuscular route of administration, diluting the preparation, and changing to an alternative type of interferon have all been advocated.\[[@ref10]\] Rotating injection sites with each dose should also help minimize the risk of injection site necrosis. Finally, surgical interventions are cosmetically helpful and reduce wound management time.\[[@ref9]\]

CONCLUSION {#sec1-4}
==========

This case report demonstrates that ulcers associated with subcutaneous IFN-β-1b treatment should be considered in the differential diagnosis of patients with an ulcerated injection-site. A literature review revealed that interferon-induced necrotic ulcers are a rare, but possible, complication of IFN-β-1b treatment. Neurologists need to be aware of the association between IFN-β treatment and severe skin reactions such as cutaneous ulceration and necrosis, and promptly refer patients who are developing skin lesions for further evaluation. Speedy and appropriate management of these side effects related to IFN-β treatment would greatly improve the adherence of MS patients to treatment, as would be taught a suitable method for self-injection by their physicians.
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